Overview

A Study to Evaluate the Efficacy and Safety of Niraparib Novel Treatment Combinations in Participants With Recurrent Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2025-06-12

Target enrollment:

Participant gender:

Summary

Niraparib is an orally available, potent, highly selective poly adenosine diphosphate-ribose polymerase (PARP) 1 and PARP2 inhibitor. This study is to evaluate the efficacy and safety of niraparib novel treatment combinations in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer. The purpose of this study is to evaluate the efficacy and safety of novel combinations of niraparib with other agents with strong scientific rationale for synergistic activity in participants with recurrent ovarian cancer. This study will consist of screening, treatment and end of treatment periods.

Phase:

Phase 2

Details

Lead Sponsor:

Tesaro, Inc.

Treatments:

Bevacizumab
Niraparib